Botanix Pharmaceuticals Limited
BXPHF
$0.099
-$0.001-1.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.68M | 2.50M | 1.36M | 1.36M | 1.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.68M | 2.50M | 1.36M | 1.36M | 1.36M |
| Cost of Revenue | 2.42M | 2.48M | 2.56M | 2.48M | 2.40M |
| Gross Profit | 1.26M | 20.60K | -1.20M | -1.12M | -1.04M |
| SG&A Expenses | 53.22M | 38.80M | 24.72M | 16.54M | 8.10M |
| Depreciation & Amortization | 1.47M | 1.12M | 781.10K | 419.50K | 47.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.10M | 42.40M | 28.06M | 19.45M | 10.54M |
| Operating Income | -53.42M | -39.90M | -26.70M | -18.08M | -9.18M |
| Income Before Tax | -55.60M | -40.59M | -25.94M | -17.66M | -9.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -55.60 | -40.59 | -25.94 | -17.66 | -9.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.60M | -40.59M | -25.94M | -17.66M | -9.10M |
| EBIT | -53.42M | -39.90M | -26.70M | -18.08M | -9.18M |
| EBITDA | -51.96M | -38.78M | -25.92M | -17.67M | -9.14M |
| EPS Basic | -0.03 | -0.02 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.02 | -0.01 | -0.01 | -0.01 | 0.00 |
| EPS Diluted | -0.03 | -0.02 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.02 | -0.01 | -0.01 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 7.38B | 7.07B | 6.76B | 6.38B | 6.01B |
| Average Diluted Shares Outstanding | 7.38B | 7.07B | 6.76B | 6.38B | 6.01B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |